J. Molimard

Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

P. Soubrié, D. Gully, M. Canton, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Primary T-cell rich B-cell lymphoma of the common bile duct

J. Molimard, P. Valleur, A. Galian, 2005, Virchows Archiv A.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

P. Soubrié, D. Gully, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

J. Simiand, P. Soubrié, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma-aminobutyric acid acting as selective GABA-A antagonists.

C. Wermuth, J. Molimard, M. Héaulme, 1987, Journal of medicinal chemistry.

Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site

C. Wermuth, J. Molimard, M. Héaulme, 1986, Brain Research.

Anticonvulsant activity of 4,9-dioxo-5,10-diazatetradecane (CM 40142), a new GABA derivative, in mice and photosensitive baboons).

J. Molimard, R. Leyris, R. Roncucci, 1984, Arzneimittel-Forschung.